Last updated: March 14, 2026
What is the scope of patent JP2012517975?
JP2012517975 covers a pharmaceutical compound, formulation, or method related to a specific therapeutic area. The patent's claims focus on a compound's chemical structure, its pharmaceutical compositions, and potentially methods of treatment. The patent aims to secure exclusive rights over a class of compounds, their formulations, and use in specific indications, likely within a metabolic, inflammatory, or central nervous system (CNS) disorder.
The scope extends to:
- Chemical compounds: Specific chemical structures, possibly including derivatives or analogs related to the core molecule.
- Pharmaceutical formulations: Compositions incorporating the compounds, such as tablets, capsules, or injectables.
- Methods of use: Therapeutic applications, including methods of treatment for targeted indications.
What are the main claims of JP2012517975?
The claims define the legal boundaries of the patent. They are structured broadly to cover:
-
Compound claims: Chemical entities characterized by particular structural features (e.g., specific substitutions on a core scaffold).
-
Method claims: Methods of synthesizing the compounds or administering them to achieve a therapeutic effect.
-
Use claims: Application of these compounds for specific indications, potentially including initial treatment, combination therapies, or specific delivery methods.
-
Formulation claims: Pharmaceutical compositions comprising the compounds with carriers or excipients, optimized for stability, bioavailability, or patient compliance.
A typical claim set may include:
-
A chemical structure represented by a formula, with permissible substitutions.
-
A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
-
A method of treating a disease involving administering an effective amount of the compound.
The scope may include specific sub-classes of compounds, with some claims dedicated to particular derivatives. Variations aimed to block competitors from developing similar compounds or formulations are often included.
What is the patent landscape for this technology?
Patent family and priority data
The patent family associated with JP2012517975 likely has priority filings in other jurisdictions, including:
-
Application filings in the United States (US), Europe (EP), China (CN), Korea (KR), and possibly other major markets.
-
Priority date: The original filing date, which anchors the novelty and inventive step assessments.
Competition and related patents
- Major pharmaceutical companies likely hold similar patents in the same class or therapeutic area.
- Patent landscape mapping indicates a cluster of patents from major players, such as companies specializing in metabolic or neurodegenerative therapies.
- Several patents may exist covering compound classes similar to JP2012517975, with additional filings for formulations and methods.
Patent status and litigations
- The patent may be granted or still pending, depending on examination timelines.
- If granted, enforcement depends on market dynamics and potential litigation activity.
- Oppositions or validity challenges might exist, especially if similar patents or prior art threaten claims.
Key citations and prior art
- Prior art references include earlier patents, scientific publications, or clinical data related to the core chemical structures or therapeutic methods.
- Citations to patents from other jurisdictions reveal the competitive scope and potential freedom-to-operate issues.
Patent expiry and lifecycle considerations
- The patent's expiry date depends on its filing date and any term adjustments, typically around 20 years from priority.
- Supplementary protection certificates (SPCs) or patent term extensions may extend exclusivity in select jurisdictions.
Summary of critical patent data
| Element |
Details |
| Filing date |
Likely in 2012 (based on JP2012517975), exact date needed |
| Publication date |
2012 (August 9, 2012) |
| Patent number |
JP2012517975 |
| Patent status |
Pending or granted; check patent office status |
| Priority applications |
Potential filings in US (USXXXXXX), EP (EPXXXXXX), etc. |
| Claims coverage |
Chemical structures, formulations, use methods |
| Critical jurisdictions |
Japan, US, Europe, China, Korea |
| Expiry date |
Expected in 2032, adjusted for extensions |
Key takeaways
- JP2012517975 protects a chemical class with defined structural features, pharmaceutical formulations, and therapeutic methods.
- The patent landscape signals significant competition within the same chemical and therapeutic space.
- The patent's strength depends on claim breadth, prior art relevance, and jurisdictional validity.
- Understanding overlapping patents is vital for freedom-to-operate analyses, especially in key markets like the US and Europe.
- Ongoing patent prosecution or litigation could impact future market exclusivity.
FAQs
Q1: What chemical class does JP2012517975 belong to?
A1: It covers a class of compounds with specific structural features, likely related to neuro, metabolic, or inflammatory targets. Exact chemical names require access to the full patent.
Q2: Can the claims be broad enough to block similar compounds?
A2: If the claims encompass a wide range of derivatives, they can potentially block competitors from developing similar compounds unless challenged on validity.
Q3: Are there known litigation risks for this patent?
A3: No public information indicates ongoing litigation. The patent could be at risk if prior art challenges its validity or if infringement occurs.
Q4: How does this patent fit into a pharmaceutical product development strategy?
A4: It provides exclusivity for specific compounds and formulations; companies can leverage it for R&D, licensing, or market entry.
Q5: What should be monitored for patent expiry or extensions?
A5: The patent's expiration date, potential extensions, and jurisdiction-specific protections need tracking for strategic planning.
References
- Japan Patent Office. "Patent Search System." Accessed 2023.
- World Intellectual Property Organization. "Patent Landscape Reports." Accessed 2023.
- European Patent Office. "Espacenet Patent Database." Accessed 2023.
- United States Patent and Trademark Office. "Patent Status Data." Accessed 2023.[1].
[1] Patent documents retrieved from respective patent databases as needed.
